ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 11 (4) 749-759    DOI: 10.1677/erc.1.00811
Copyright © 2004 by the Society for Endocrinology.
This Article
Right arrow Free Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yanagawa, T
Right arrow Articles by Raz, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanagawa, T
Right arrow Articles by Raz, A

REVIEW

Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy

T Yanagawa, T Funasaka, S Tsutsumi1, H Watanabe2 and A Raz

Tumor Progression and Metastasis, Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, Michigan 48201, USA
1 Department of General Surgical Science (Surgery I), Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan
2 Department of Orthopedic Surgery, Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan

(Requests for offprints should be addressed to A Raz, Tumor Progression and Metastasis, Karmanos Cancer Institute, 110 East Warren Avenue, Detroit, Michigan 48201, USA; Email: raza{at}karmanos.org.)

Autocrine motility factor (AMF) stimulates cell motility in an autocrine manner and is related to tumor malignancy. AMF is a multifunctional molecule, also known as phosphoglucose isomerase and neuroleukin. Signal cascades of the AMF-stimulated motility and novel functions of this protein contributing to tumor malignancy have been presented recently. AMF stimulation activated small Rho-like GTPases and subsequently induced actin fiber rearrangement, which was removed by the C3 exoenzyme, a specific inhibitor of Rho. The expression of Jun N-terminal kinase (JNK)1, JNK2 and the Rho GDP dissociation inhibitor-ß was upregulated by AMF. The addition of AMF to culture medium stimulated the motility of the endothelial cells and the formation of tube-like structures in collagen gels. Highly AMF-expressing HT1080 cells induced aggressive angiogenesis in vivo. The expression of fms-like tyrosine kinase (Flt)-1, a vascular endothelial growth factor (VEGF) receptor, was enhanced in AMF-expressing tumors dependent on protein kinase C and phosphatidylinositol 3 kinase (PI3K) activation; meanwhile kinase insert domain-containing receptor, another receptor of VEGF, was not. Permeability of mesothelial and endothelial cell monolayers was increased by AMF, and numerous gaps were observed in the monolayers after treatment with AMF. AMF gene transfection transformed NIH3T3 cells to proliferate quickly and acquire anti-apoptosis ability induced by serum deprivation in a PI3K-dependent manner. The anti-apoptotic effect of AMF has been described by other authors who have shown that the AMF over-expressing cells were resistant to mitomycin-C-induced apoptosis showing regression of Apaf-1 and caspase-9 dependent on PI3K and MAP kinase. These novel functions of AMF makes it a likely target for cancer therapy.




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
J. G. Goetz, H. Genty, P. St-Pierre, T. Dang, B. Joshi, R. Sauve, W. Vogl, and I. R. Nabi
Reversible interactions between smooth domains of the endoplasmic reticulum and mitochondria are regulated by physiological cytosolic Ca2+ levels
J. Cell Sci., October 15, 2007; 120(20): 3553 - 3564.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society for Endocrinology.